Paper Details

  1. Home
  2. Paper Details

Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival.

Author: , AliSahra, BowenDavid, BurnettAlan K, HillsRobert K, HunterAnn E, KnapperSteven, McMullinMary F, MilliganDonald, RussellNigel H, WheatleyKeith, YinJohn

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study compared two treatments for older adults with acute myeloid leukemia (AML) who were not healthy enough for intensive chemotherapy. The study found that clofarabine significantly increased the rate of complete remission (22% vs 12%) and overall response (38% vs 19%) compared to low-dose Ara-C. However, there was no difference in overall survival, likely due to poorer survival in patients who didn't achieve complete remission and after relapses. Clofarabine also caused more side effects requiring additional care. While clofarabine doubled remission rates, it didn't improve overall survival, highlighting the ongoing need for better treatments for this population.
Paper Details　
Original Abstract of the Article :
Better treatment is required for older patients with acute myeloid leukemia (AML) not considered fit for intensive chemotherapy. We report a randomized comparison of low-dose Ara-C (LDAC) vs the novel nucleoside, clofarabine, in untreated older patients with AML and high-risk myelodysplastic syndrom...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1182/blood-2013-04-496596

データ提供：米国国立医学図書館（NLM）

Clofarabine for Older Patients with Acute Myeloid Leukemia: A Promising but Complex Treatment

This research delves into the challenging world of acute myeloid leukemia (AML), a type of cancer that affects the blood and bone marrow. Think of AML as a relentless desert sandstorm that overwhelms the body's defenses. The study investigated the use of clofarabine, a novel chemotherapy drug, in older patients with AML who were not eligible for intensive chemotherapy. The results show that clofarabine significantly improved the remission rate in these patients, but did not improve overall survival. This finding highlights the complexity of AML treatment and the need for further research to find more effective therapies for older patients.

Clofarabine: A Double-Edged Sword in AML Treatment

This study explores the use of clofarabine in older patients with AML, offering a promising but complex treatment option. The findings show that clofarabine improved remission rates but did not improve overall survival. This highlights the need for further research to understand how to best utilize clofarabine and develop more effective treatments for older patients with AML.

Navigating AML Treatment: A Team Effort

AML treatment often requires a multi-disciplinary approach, involving oncologists, hematologists, and other healthcare professionals. Open communication and close monitoring are essential for ensuring the best possible outcome for patients with AML.

Dr.Camel's Conclusion

This research provides valuable insights into the use of clofarabine in older patients with AML, offering a promising but complex treatment option. It highlights the need for further research to develop more effective therapies for this challenging disease.
Date :
  1. Date Completed 2013-11-05
  2. Date Revised 2021-02-02
Further Info :

Pubmed ID

23838349

DOI: Digital Object Identifier

10.1182/blood-2013-04-496596

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.